Copyright © 2007, European Society of Cardiology
Inhaled NO as a therapeutic agent
Cardiovascular Research Center and the Department of Anesthesia and Critical Care, Massachusetts General Hospital and Harvard Medical School, United States
* Corresponding author. Anesthesia Center for Critical Care Research, Thier 5, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, United States. Tel.: +1 617 724 9540; fax: +1 617 726 3032. kdbloch{at}partners.org
In 1991, Frostell and colleagues reported that breathing low concentrations of nitric oxide (NO) decreased pulmonary artery pressure (PAP) in awake lambs with experimental pulmonary hypertension (PH) [Frostell C, Fratacci MD, Wain JC, Jones R, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991;83:2038–47]. Subsequently, efforts of multiple research groups studying animals and patients led to approval of inhaled NO by the US Food and Drug Administration in 1999 and the European Medicine Evaluation Agency and European Commission in 2001. Inhaled NO is currently indicated for the treatment of term and near-term neonates with hypoxemia and PH. Since regulatory approval, several studies have suggested that NO inhalation can prevent chronic lung disease in premature infants. In addition, unanticipated systemic effects of inhaled NO may lead to treatments for a variety of disorders including ischemia-reperfusion injury.
This review summarizes the pharmacology and physiological effects of breathing NO. The application of inhaled NO to hypoxemic neonates with PH is discussed including recent studies exploring the use of inhaled NO to prevent bronchopulmonary dysplasia in premature infants. This review also highlights the application of inhaled NO to treat adults with cardiopulmonary disease, strategies to augment the efficacy of inhaled NO, and potential applications of the systemic effects of the gas.
KEYWORDS Pulmonary circulation; Nitric oxide
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Zhang, L. Zhou, Q. Li, J. Liu, W. Yao, and H. Wan Up-Regulation of Two Actin-Associated Proteins Prompts Pulmonary Artery Smooth Muscle Cell Migration under Hypoxia Am. J. Respir. Cell Mol. Biol., October 1, 2009; 41(4): 467 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lee, R. Reich, F. Xu, and P. B. Sehgal Golgi, trafficking, and mitosis dysfunctions in pulmonary arterial endothelial cells exposed to monocrotaline pyrrole and NO scavenging Am J Physiol Lung Cell Mol Physiol, October 1, 2009; 297(4): L715 - L728. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. B. Sehgal, S. Mukhopadhyay, K. Patel, F. Xu, S. Almodovar, R. M. Tuder, and S. C. Flores Golgi dysfunction is a common feature in idiopathic human pulmonary hypertension and vascular lesions in SHIV-nef-infected macaques Am J Physiol Lung Cell Mol Physiol, October 1, 2009; 297(4): L729 - L737. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Kobzik Translating NO Biology into Clinical Advances: Still Searching for the Right Dictionary? Am. J. Respir. Cell Mol. Biol., July 1, 2009; 41(1): 9 - 13. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Yu, M. J. Raher, G. P. Volpato, K. D. Bloch, F. Ichinose, and W. M. Zapol Inhaled Nitric Oxide Enables Artificial Blood Transfusion Without Hypertension Circulation, April 15, 2008; 117(15): 1982 - 1990. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Lamas, C. J. Lowenstein, and T. Michel Nitric oxide signaling comes of age: 20 years and thriving Cardiovasc Res, July 15, 2007; 75(2): 207 - 209. [Full Text] [PDF]
|
|